(NASDAQ: ATYR) Atyr Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.27%.
Atyr Pharma's earnings in 2026 is -$74,118,000.On average, 12 Wall Street analysts forecast ATYR's earnings for 2026 to be -$60,262,275, with the lowest ATYR earnings forecast at -$73,028,543, and the highest ATYR earnings forecast at -$39,122,434. On average, 11 Wall Street analysts forecast ATYR's earnings for 2027 to be -$46,505,690, with the lowest ATYR earnings forecast at -$63,419,524, and the highest ATYR earnings forecast at -$11,324,915.
In 2028, ATYR is forecast to generate -$21,571,267 in earnings, with the lowest earnings forecast at -$58,615,015 and the highest earnings forecast at $108,101,461.